US 12,203,933 B2
Methods and materials for identifying and treating membranous nephropathy
M. Cristine Charlesworth, Rochester, MN (US); Sanjeev Sethi, Rochester, MN (US); Fernando C. Fervenza, Rochester, MN (US); and Benjamin J. Madden, Stewartville, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 17/254,086
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Aug. 15, 2019, PCT No. PCT/US2019/046676
§ 371(c)(1), (2) Date Dec. 18, 2020,
PCT Pub. No. WO2020/037135, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/764,681, filed on Aug. 15, 2018.
Prior Publication US 2021/0270832 A1, Sep. 2, 2021
Int. Cl. G01N 33/564 (2006.01)
CPC G01N 33/564 (2013.01) [G01N 2333/705 (2013.01); G01N 2333/91102 (2013.01); G01N 2800/347 (2013.01)] 17 Claims
 
1. A method for treating a mammal having membranous nephropathy, wherein said method comprises administering an immunosuppressant to a mammal identified as having (i) autoantibodies specific for a polypeptide or (ii) kidney tissue comprising an elevated level of said polypeptide as compared to a level of said polypeptide in normal kidney tissue, wherein said polypeptide is an exostosin 1 (EXT1) polypeptide or an exostosin 2 (EXT2) polypeptide.